Answers are grounded in this paper and cite their sources.
A randomized trial investigates the effects of multimodal neurologic enhancement on clinical outcomes in preterm infants, suggesting potential benefits for extremely preterm infants.
This study evaluated the impact of Multimodal Neurologic Enhancement (MNE), a music therapy intervention, on clinical outcomes of preterm infants (< 34 weeks; N = 106) and a subgroup of extremely preterm infants (< 28 weeks; n = 20). A randomized trial was utilized, where infants were randomized to receive MNE or standard of care and matched based on gestational age at birth, sex, and neurologic injury. Infants in the MNE group received eight, 20-minute MNE sessions, beginning at 32 weeks post menstrual age (PMA). Analysis included negative binomial and linear regression, adjusting for relative covariates. Across the full cohort and the extremely preterm subgroup, there were no significant differences in PMA at discharge, duration of oxygen therapy (days), PMA at transition off oxygen therapy, or transition to full oral feeding (days). Among the extremely preterm subgroup, MNE was associated with a significantly shorter length of stay (days) (IRR = 0.81, corresponding to β ̂ = −0.21; 95% CI for IRR: 0.68, 0.98). These findings suggest that MNE may offer targeted benefits for extremely preterm infants. This study highlights the potential of MNE as a safe, feasible intervention to support clinical outcomes during Neonatal Intensive Care Unit admission for preterm infants. • Multimodal Neurologic Enhancement (MNE) is safe and feasible for preterm infants. • MNE significantly reduced length of stay for extremely preterm infants. • MNE resulted in no significant differences in preterm infants' clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Pivovarnik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: